Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving tadasitamab and rituximab may work well to treat patien

Trial Details

NCT ID

NCT07731789

Phase

PHASE2

Sponsor

University of Washington

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Rituximab
Tafasitamab
Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Computed Tomography

Locations (sample)

Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

Age ≥ 18 years old
Patients must have histologic confirmation of follicular lymphoma (FL) (grade 1, 2, and 3A or classic follicular lymphoma)
Meeting any one of the following criteria for therapy initiation:
Involvement of ≥ 3 nodal sites, each with diameter of ≥ 3 cm.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →